## Healthcare Resource Use and Costs Associated with Herpes Zoster/Postherpetic Neuralgia Episodes in Italy: A Retrospective Observational Study

Zarkadoulas E<sup>1</sup>, Santacroce R<sup>2</sup>, Comparoni S<sup>2</sup>, Freguja R<sup>2</sup>, Veronesi C<sup>3</sup>, Dovizio M<sup>3</sup>, Degli Esposti L<sup>3</sup>

<sup>1</sup>GSK, Wavre, Belgium; <sup>2</sup>GSK, Verona, Italy; <sup>3</sup>CliCon S.r.l. Società Benefit Health, Economics & Outcomes Research, Bologna, Italy

### Supplementary material

#### Definitions: immunocompromised (IC) and chronic conditions (CC)

- IC included: Hematopoietic Stem Cell Transplantation, Organ Transplantation, Tumors, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Inflammatory Bowel Disease, Psoriasis, End-stage renal disease and those on Immunosuppressive therapy, Human immunodeficiency virus (HIV)
- Chronic conditions included: Chronic obstructive pulmonary disease (COPD), Diabetes, Dyslipidemia, Hypertension, Cardiovascular Events (e.g. Stroke, Heart Failure, Acute Myocardial Infarction, Atrial Fibrillation) and Cardiovascular Procedures

#### Treatments during follow-up periods of HZ/PHN patients ≥50 years (N=145,923)

| Presence of treatment (at least one) N(%) | 144,282 (98.9) |  |  |
|---|----------------|--|--|
| Brivudine, n (%)                          | 142,428 (97.6) |  |  |
| Acyclovir, n (%)                          | 6,116 (4.2)    |  |  |
| Valacyclovir, n (%)                       | 1,677 (1.1)    |  |  |
| Famciclovir, n (%)                        | 827 (0.6)      |  |  |
| Immunosuppressant medications, n (%)      | 2,165 (1.5)    |  |  |
| Systemic glucocorticoids, n (%)           | 37,170 (25.5)  |  |  |

#### Clinical characteristics of HZ patients ≥50 years (N=145,923) evaluated during the characterization periods

| IC patients - presence of treatment (at least one), N(%) | 43,607 (29.9) | CC patients - presence of conditions (at least one), N(%) | 110,978 (76.1) |
|--|---------------|---|----------------|
| Hematopoietic Stem Cell Transplantation, n (%)           | 23 (0.0)      | Diabetes, n (%)   | 24,274 (16.6)  |
| Organ Transplantation, n (%)                             | 126 (0.1)     | Dyslipidemia, n (%)                                       | 48,768 (33.4)  |
| Tumors*, n (%)   | 10,570 (7.2)  | Hypertension, n (%)                                       | 95,026 (65.1)  |
| Rheumatoid Arthritis*, n (%)                             | 783 (0.5)     | COPD, n (%)   | 35,033 (24.0)  |
| Systemic Lupus Erythematosus*, n (%)                     | 51 (0.0)      | Cardiovascular Events, n (%)                              | 6,516 (4.5)    |
| Inflammatory Bowel Disease*, n (%)                       | 243 (0.2)     | Stroke, n (%)   | 2,059 (1.4)    |
| Psoriasis*, n (%)  | 87 (0.1)      | Heart Failure, n (%)                                      | 1,586 (1.1)    |
| HIV, n (%)   | 25 (0.0)      | Acute Myocardial Infarction, n (%)                        | 2,263 (1.6)    |
| End-stage renal disease, n (%)                           | 321 (0.2)     | Atrial Fibrillation, n (%)                                | 1,750 (1.2)    |
| Immunosuppressive Therapy, n (%)                         | 36,588 (25.1) | Cardiovascular Procedures, n (%)                          | 2,176 (1.5)    |

<sup>\*=</sup>Exemption code reserched during all available period before index date

# Average and total direct healthcare costs (€) of overall hospital stays for HZ patients without PHN and per type of HZ hospitalization during follow-up period

| Diagnosis at Hospitalization discharge (ICD-9-CM code)   | Patients with at least one Hospitalization | Mean Per Hospitalized Patient (€) | Total Hospitalizations (€) |  |
|--|--|-----------------------------------|----------------------------|--|
| HZ without PHN   | 778  | 3,704.43                          | 2,882,044.19               |  |
| HZ with meningitis (053.0)   | 11   | 4,796.16                          | 52,757.81                  |  |
| HZ with nervous system complications not specified (053.10)  | 29   | 3,583.02                          | 103,907.70                 |  |
| HZ del ganglio geniculate (053.11)   | 5  | 2,812.65                          | 14,063.27                  |  |
| HZ myelitis (053.14)   | 5  | 4,926.17                          | 24,630.86                  |  |
| HZ with other complications of the nervous system (053.19)   | 56   | 3,572.36                          | 200,052.40                 |  |
| Dermatitis of the eyelves from HZ (053.20)   | 20   | 3,731.54                          | 74,630.78                  |  |
| Keratoconjunctivitis from HZ (053.21)  | 46   | 3,667.28                          | 168,695.09                 |  |
| Iridocyclite by HZ (053.22)  | <4   | NI                                | NI                         |  |
| HZ with other ophthalmic complications (053.29)  | 26   | 3,524.45                          | 91,635.82                  |  |
| External otite from HZ (053.71)  | 13   | 3,320.55                          | 43,167.20                  |  |
| HZ with other specified complications (053.79)   | 64   | 3,671.36                          | 234,967.01                 |  |
| HZ with not specified complications (053.8)  | 38   | 4,037.77                          | 153,435.33                 |  |
| HZ without mention of complications (053.9)  | 483  | 3,630.53                          | 1,753,543.59               |  |
| NI (sample size <4; data not reported for privacy reasons) ICD-9-CM = internation classification of diseases, ninth revision, clinical mod | ification                                  |                                   |                            |  |

#### Average Healthcare Resource Consumption During the First Year of Follow up Period, Post PSM

|                 | •         |           |          | •        |           |           |          |          |
|-----------------|-----------|-----------|----------|----------|-----------|-----------|----------|----------|
|                 | Overall   |           | IC       |          | СС        |           | Oncology |          |
|                 | No HZ     | HZ        | No HZ    | HZ       | No HZ     | HZ        | No HZ    | HZ       |
|                 | N=193,259 | N=193,259 | N=51,687 | N=51,687 | N=121,984 | N=121,984 | N=11,619 | N=11,619 |
| Drugs           | 10.1      | 14.2      | 16.3     | 19.7     | 16.0      | 19.3      | 17.0     | 20.0     |
| Hospitalization | 0.1       | 0.2       | 0.3      | 0.3      | 0.2       | 0.3       | 0.4      | 0.5      |
| Outpatient      | 2.6       | 3.4       |          |          | 3.9       | 4.3       |          |          |
| Service         | 2.0       | 3.4       | 4.7      | 5.1      | 3.9       | 4.3       | 7.3      | 7.5      |
| Total           | 12.8      | 17.8      | 21.3     | 25.1     | 20.1      | 23.9      | 24.7     | 28.0     |

#### **Abbreviations**

CC, chronic condition; COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus; HZ, herpes zoster; IC, immunocompromised; NI, not implemented; PHN, postherpetic neuralgia; PSM, propensity score matching